INSMED INC (INSM) Stock Price, Quote, News and Overview
NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD
INSM Quote, Performance and Key Statistics
NASDAQ:INSM (3/3/2025, 3:53:07 PM)
75.97
-5.58 (-6.84%)
The current stock price of INSM is 75.97 USD. In the past month the price increased by 6.89%. In the past year, price increased by 190.63%.
INSM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.88 | 373.43B | ||
| AMGN | AMGEN INC | 15.62 | 166.25B | ||
| GILD | GILEAD SCIENCES INC | 25.1 | 144.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1667.79 | 124.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.03 | 75.00B | ||
| ARGX | ARGENX SE - ADR | 242.06 | 37.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.26B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.14B | ||
| BIIB | BIOGEN INC | 8.63 | 20.72B | ||
| NTRA | NATERA INC | N/A | 18.82B | ||
| GMAB | GENMAB A/S -SP ADR | 24.62 | 14.54B |
Related stock screener links
About INSM
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 912 full-time employees. The firm's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Company Info
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807 US
CEO: William H. Lewis
Employees: 912
Company Website: https://insmed.com/
Investor Relations: https://investor.insmed.com/index
Phone: 19089779900
INSMED INC / INSM FAQ
What is the stock price of INSMED INC today?
The current stock price of INSM is 75.97 USD. The price decreased by -6.84% in the last trading session.
What is the ticker symbol for INSMED INC stock?
The exchange symbol of INSMED INC is INSM and it is listed on the Nasdaq exchange.
On which exchange is INSM stock listed?
INSM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INSMED INC stock?
23 analysts have analysed INSM and the average price target is 92.77 USD. This implies a price increase of 22.11% is expected in the next year compared to the current price of 75.97. Check the INSMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INSMED INC worth?
INSMED INC (INSM) has a market capitalization of 13.59B USD. This makes INSM a Large Cap stock.
How many employees does INSMED INC have?
INSMED INC (INSM) currently has 912 employees.
What are the support and resistance levels for INSMED INC (INSM) stock?
INSMED INC (INSM) has a support level at 80.54. Check the full technical report for a detailed analysis of INSM support and resistance levels.
Is INSMED INC (INSM) expected to grow?
The Revenue of INSMED INC (INSM) is expected to grow by 37.17% in the next year. Check the estimates tab for more information on the INSM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INSMED INC (INSM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INSM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INSM, evaluating the profitability, health, valuation and growth aspects
- INSMED INC (INSM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INSMED INC (INSM) Sales and EPS estimates to see what analysts future expectations are.
- INSMED INC (INSM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INSMED INC (INSM) Insider and Institutional Ownership to learn about the owners and their transactions.
- INSMED INC (INSM) Stock Chart to make your own analysis
- INSMED INC (INSM) Latest news and press-releases to stay up to date.
Does INSMED INC (INSM) stock pay dividends?
INSM does not pay a dividend.
When does INSMED INC (INSM) report earnings?
INSMED INC (INSM) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of INSMED INC (INSM)?
INSMED INC (INSM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.58).
What is the Short Interest ratio of INSMED INC (INSM) stock?
The outstanding short interest for INSMED INC (INSM) is 8.23% of its float. Check the ownership tab for more information on the INSM short interest.
INSM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 98.01% of all stocks.
INSM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INSM. Both the profitability and financial health of INSM have multiple concerns.
INSM Financial Highlights
Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -5.58. The EPS decreased by -4.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.12% | ||
| ROE | -320.2% | ||
| Debt/Equity | 3.95 |
INSM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to INSM. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of 16.18% and a revenue growth 37.17% for INSM